The University of Texas MD Anderson Cancer Center today named Welela Tereffe, M.D., as chief medical executive (CME). Recognized as a patient-centered and institutionally minded leader, Tereffe assumes this new position and joins the institution’s Executive Leadership Team (ELT) on […]
University of Texas MD Anderson Cancer Center
Md Anderson And Obsidian Therapeutics Announce Strategic Collaboration To Accelerate Advancement Of Novel Engineered Tumor Infiltrating Lymphocyte Therapy (Cytotil) For Solid Tumors
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and […]
Study identifies characteristics of infused CAR T cells associated with efficacy and toxicity in patients with large B-cell lymphoma
Findings suggest that monitoring early changes in circulating tumor DNA may predict patient outcomes Researchers at The University of Texas MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma (LBCL) respond to […]
